Diffuse large B cell lymphoma (DLBCL), as the most common subtype non-Hodgkin lymphoma (NHL),
has great heterogeneity in clinical manifestations, histological morphology and prognosis.
R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the
gold therapeutic criteria for patients with NHL, and it is also used as the first-line
treatment for patients with DLBCL. After treatment, 50％～60％of patients with DLBCL receive
complete remission (CR), 30％～40％ recurrent and 10% will never be cured due to initial and
secondary drug tolerance. This study aimed to explore whether Cinobufacini Tablets had
synergistic effect in the treatment of DLBCL, and whether its action was in close association
with the positive expression of Na+/K+-ATPase α3, and to observe the rates of adverse
reactions induced by Cinobufacini Tablets during treatment.